Gate2Brain
  • Home
  • Company
  • Team
  • Technology
  • Pipeline-Proof of Concept
  • Investors
  • News & Media
  • Contact
  • Menu Menu

The drug booster to the brain

News
Sometimes drugs need a bigger push to be more effective and reach their final destination:Expansion

Sometimes drugs need a bigger push to be more effective and reach their final destination: the brain. The three families of peptides (proteins) developed and patented by Gate2Brain fulfill this mission by acting as a shuttle or tractor for drugs to act on this organ and treat localized pathologies.

This development led by Meritxell Teixidó, CEO of the company, after several years of work, has been possible thanks to a team of researchers and professionals from the University of Barcelona, ​​IRB Barcelona and Hospital Sant Joan de Déu. The first application of this technology will be for the treatment of pediatric cancer, when it is located in the brain.

“We are currently in the preclinical phase and the first clinical trial with pediatric patients is scheduled for 2026, at the Sant Joan de Déu Hospital, a reference center for childhood diseases”, explains Teixidó. The company has recently drawn the attention from the EIC Accelerator program of the European Union, which has injected 2.5 million euros into it.

Source: Expansión Start Up

February 28, 2023/by noticias
Tags: Biotech, Expansión, pediatriccancer, research, Startup
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail
https://gate2brain.com/wp-content/uploads/2023/02/Copia-de-Fashion-Quote-Instagram-feed-post-3.png 1080 1080 noticias https://gate2brain.com/wp-content/uploads/2020/12/Logo-Gate1Brain500pxGrueso.png noticias2023-02-28 10:41:162023-02-28 11:28:37The drug booster to the brain
You might also like
It’s Gate2Brain second anniversary!! 🎂 The creativity, work and dedication of Gate2Brain's team can only be matched with its desire to bring medicines beyond barriers.Gate2BrainGate2Brain second anniversary
Next Wednesday, February 16, @Gate2Brain will be in #Transfiere, European Forum for Science, Technology and Innovation to be held in Malaga. Our CEO, @Meritxell Teixidó, will participate as a speaker together with 16 other companies, at the #Boosting Zone for being one of the companies that have been awarded the #NEOTEC2021 program of the @CDTI, Centro para el Desarrollo Tecnológico Industrial. Boosting Zone is a space for promoting innovation and technology transfer from scientific-based companies.TransfiereGate2Brain in Transfiere – European Forum for Science, Technology & Innovation
‘Tractor’ proteins that carry drugs to the brain as therapy for incurable pediatric cancer
CaixaImpulsGate2Brain as alumni at Caixa Impulse Validate
Meritxell Teixidó (Gate2Brain, Medicines Beyond Barriers): “Utilitzem una nova tecnologia basada en pèptids per millorar el transport de fàrmacs al cervell”Meritxell Teixidó (Gate2Brain, Medicines Beyond Barriers): “We use a new technology based on peptides to improve the transport of drugs to the brain”
Many drugs do not reach the brain and Gate2Brain technology helps to overcome that bottleneck
Biotech New Frontiers Award 2022Gate2BrainG2B awarded with Biotech New Frontiers 2022
Una tecnología para ayudar a tratar el cáncer infantilgate2brainA technology to help treat pediatric cancer

CATEGORIES

  • Clipping
  • Events
  • Media
  • News
  • Podcast
  • Press releases
  • Publications
  • Videos

Events

  • The innovative biopharmaceutical industry, a lever for economic and social well-being. A comprehensive approach”, organized by Foment del Treball.Foment del TreballThe innovative biopharmaceutical industry, a lever for economic and social well-being. A comprehensive approach.March 23, 2023 - 08:54
  • G2B at 4YFN 2023G2BGate2Brain at 4YFN-MWC23March 3, 2023 - 08:24
  • Gate2Brain at TransfiereG2BG2B at Transfiere 2023February 17, 2023 - 07:45
  • 📢 On December 13h, Gate2Brain will be participating together with Maribel Berges (AFFIRMA BIOTECH SL), Sven Dr. Mulfinger (Dana_positive maternal health), and Diana Ballart (The Smart Lollipop) in the i4kids Closing Event 2022, sharing achievements and failures of entrepreneurs in #pediatric and maternal #healthcare.i4kidsi4kids Closing Event 2022December 7, 2022 - 12:37
  • WomenStartupAwards, in the "Inspiration" category.WomeninTechSpainFinalist of Women Startup AwardsNovember 15, 2022 - 17:46

SOCIAL

  • linkedin
  • youtube

RSS RSS Ciencia

  • Barcelona to host BIO-Europe Spring 2024 March 23, 2023 biocat
  • 4YFN 2023 sees record turnout, surpassing all expectations March 6, 2023 biocat
  • European health clusters tackle sector’s main challenges in international framework February 24, 2023 biocat
  • Sector experts review main strategic challenges facing BioRegion of Catalonia February 23, 2023 biocat
  • Different health clusters in Ukraine know about the BioRegion thanks to Biocat February 23, 2023 biocat
  • Biocat and Alira Health launch market access program for BioRegion startups February 23, 2023 biocat
  • CRAASH Barcelona celebrates 5th anniversary February 23, 2023 biocat
  • Highlights: New historic record for investment in the BioRegion, new funding, more acquisitions, and ground-breaking research into strokes February 23, 2023 biocat
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social

  • linkedin
  • youtube
© Copyright –Edisenius
  • Privacy Policy
  • Legal Notice
  • Cookie Policy
G2B at Transfiere 2023Gate2Brain at TransfiereG2BG2B at 4YFN 2023G2BGate2Brain at 4YFN-MWC23
Scroll to top
Manage Cookie Consent
This Website uses proprietary and third-party cookies to improve services and facilitate browsing. You can obtain further information about the cookies this site uses and how to limit them in the
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}